Group 1 - The core idea of the article highlights the successful completion of the B+ round financing by Nanjing Pulimeng Medical Technology Co., Ltd., led by Huatai Zijin Investment and XG Industrial Investment [1][8] - The founder Liu Ping, with a medical background, identified a gap in the medical device market during his postdoctoral research in the United States, which fueled his entrepreneurial ambition [3][5] - Pulimeng's first product, an absorbable surgical suture, was approved for market in July 2020, featuring a unique cutting process and design that significantly improves suturing effectiveness compared to traditional products [5][3] Group 2 - Over its nine years of establishment, Pulimeng has developed two key technology platforms for biodegradable polymer material preparation and personalized processing of biodegradable medical devices, resulting in over 20 self-developed products [5][7] - The company's flagship product, the absorbable knotless barbed suture, utilizes a special processing technique and has a degradation period of approximately 180 days, simplifying the suturing process and reducing surgery time [5][3] - In the aesthetic medicine sector, Pulimeng has launched a recombinant collagen dressing and completed clinical trials for its "童颜针" (youthful needle), with promising data on its PLLA microsphere particles [5][3] Group 3 - The industrialization base project of Pulimeng was selected as a major project in Jiangsu Province for 2024, which has been completed and is set to enhance the company's production capacity and technological innovation [7][8] - The company has undergone multiple financing rounds, including nearly 100 million yuan in A round financing in 2022 and close to 200 million yuan in B round financing in 2023, with the latest B+ round financing amount undisclosed [8][7]